Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Akhil Chawla

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3122-6873; OpenAlex author ID A5032656184; NIH RePORTER profile ID 11425618. Sources: OpenAlex.

Their work

Papers
34 (first author 4, last author 15)
Trials
0
Grants
1
Labs led
2
Collaborators
107
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 4 papers · 2021: 3 papers · 2022: 5 papers · 2023: 3 papers · 2024: 4 papers · 2025: 5 papers · 2026: 8 papers, 1 grant

Papers 34

  1. Dynamic Prognostic Nutritional Index With Circulating Tumor DNA Predicts Survival in Localized Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1002/jso.70296↗
  2. Multimodal Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma (PDAC) With Vascular Involvement: What Is the Impact of Radiation on Perioperative Outcomes… Last author DOI 10.1002/jso.70387↗
  3. Impact of Institutional Radiotherapy Patient Volume on Postoperative and Oncologic Outcomes After Neoadjuvant Radiation for Pancreatic Cancer. Co-author DOI 10.1002/jso.70401↗
  4. Quantitative KRAS mutational burden by next-generation sequencing predicts outcomes in localized pancreatic cancer Last author DOI 10.1016/j.surg.2026.110303↗
  5. Mutant KRAS in Circulating Tumor DNA as a Biomarker in Localized Pancreatic Cancer Patients Treated With Neoadjuvant Chemotherapy. Last author DOI 10.1097/sla.0000000000006562↗
  6. High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-26-0609↗
  7. KRAS and TP53 Circulating Tumor DNA are Prognostic in Localized Pancreatic Cancer. Last author DOI 10.1245/s10434-026-20447-0↗
  8. ASO Visual Abstract: KRAS and TP53 Circulating Tumor DNA are Prognostic in Localized Pancreatic Cancer Last author DOI 10.1245/s10434-026-20549-9↗
  9. The Current Role of Circulating Tumor DNA in the Management of Pancreatic Cancer. Last author DOI 10.1007/s12029-024-01129-0↗
  10. Prospective Evaluation of Circulating Tumor DNA Using Next-generation Sequencing as a Biomarker During Neoadjuvant Chemotherapy in Localized Pancreatic Cancer. Last author DOI 10.1097/sla.0000000000006209↗
  11. A comparison of outcomes for patients with localized pancreatic ductal adenocarcinoma receiving neoadjuvant chemotherapy with and without radiation prior to cu… Last author DOI 10.21037/cco-25-60↗
  12. Translating the multifaceted use of liquid biopsy to management of early disease in pancreatic adenocarcinoma. Last author DOI 10.3389/fonc.2025.1520717↗
  13. Ultra-sensitive detection of mutant KRAS in circulating tumor DNA predicts survival in resectable pancreatic adenocarcinoma. Last author DOI 10.3389/fonc.2025.1657746↗
  14. Gastrointestinal Malignancies: Pancreatic Cancer Clinical Trials in Neoadjuvant Chemotherapy. First author DOI 10.1007/978-3-031-61238-1_6↗
  15. Early detection of pancreatic cancer: Study design and analytical considerations in biomarker discovery and early phase validation studies. Co-author DOI 10.1016/j.pan.2024.10.012↗
  16. ALLIANCE A021806: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-15817-5↗
  17. Liquid-liquid phase separation-related features of PYGB/ACTR3/CCNA2/ITGB1/ATP8A1/RAP1GAP2 predict the prognosis of pancreatic cancer. Co-author DOI 10.21037/jgo-24-426↗
  18. The differential effect of neoadjuvant chemotherapy and chemoradiation on nodal downstaging in pancreatic adenocarcinoma. Last author DOI 10.1016/j.pan.2023.08.003↗
  19. Weight loss during neoadjuvant chemotherapy impacts perioperative outcomes in patients undergoing surgery for pancreatic cancer. Last author DOI 10.1016/j.pan.2023.10.006↗
  20. Surgeon-Led Clinical Trials in Pancreatic Cancer. Co-author DOI 10.1016/j.soc.2022.08.001↗
  21. Identification of high-risk germline variants for the development of pancreatic cancer: Common characteristics and potential guidance to screening guidelines. Last author DOI 10.1016/j.pan.2022.05.005↗
  22. Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Co-author DOI 10.1016/j.surg.2021.10.015↗
  23. Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004585↗
  24. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1125↗
  25. Measuring response to neoadjuvant therapy using biomarkers in pancreatic cancer: a narrative review. First author DOI 10.21037/cco-22-49↗
  26. Pancreatic Cancer: A Review. First author DOI 10.1001/jama.2021.13027↗
  27. A Review of Pancreatic Cancer-Reply. First author DOI 10.1001/jama.2021.20068↗
  28. Contemporary trials evaluating neoadjuvant therapy for resectable pancreatic cancer. Co-author DOI 10.1002/jso.26393↗
  29. Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. Co-author DOI 10.1016/j.pan.2020.03.011↗
  30. Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. Co-author DOI 10.1158/1078-0432.ccr-18-1359↗
  31. Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-08087-z↗
  32. ASO Author Reflections: Neoadjuvant Therapy for Pancreatic Cancer-Standard of Care or Still Worth Debating? Co-author DOI 10.1245/s10434-019-08135-8↗
  33. Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift. Co-author DOI 10.3389/fonc.2019.01085↗
  34. Pretherapy neutrophil to lymphocyte ratio and platelet to lymphocyte ratio do not predict survival in resectable pancreatic cancer. Co-author DOI 10.1016/j.hpb.2017.10.011↗

Grants 1

  1. National and Institutional Leadership and Support of NCI-Sponsored Clinical Trial Research as a Surgical Oncologist R50CA293523↗

Closest collaborators

The 25 strongest of 107 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dominic J. Vitello · 10 shared papers, 2025–2026 · strength 2.86
  2. M.C. Cox · 10 shared papers, 2025–2026 · strength 2.78
  3. David J. Bentrem · 8 shared papers, 2025–2026 · strength 1.95
  4. Alex Horowitz · 5 shared papers, 2026 · strength 1.25
  5. Krishay Sridalla · 5 shared papers, 2026 · strength 1.25
  6. Cristina Rosa Ferrone · 5 shared papers, 2019–2023 · strength 0.95
  7. Dhavan Shah · 4 shared papers, 2025–2026 · strength 0.93
  8. George Molina · 3 shared papers, 2020–2026 · strength 0.70
  9. Cade F. Bennett · 2 shared papers, 2022–2025 · strength 0.53
  10. Jiping Wang · 3 shared papers, 2020–2022 · strength 0.46
  11. Paola A. Barrios · 1 shared paper, 2024 · strength 0.46
  12. Wungki Park · 2 shared papers, 2021 · strength 0.44
  13. Eileen Mary O'Reilly · 2 shared papers, 2021 · strength 0.44
  14. Motaz Qadan · 4 shared papers, 2020–2022 · strength 0.44
  15. Brian Matthew Wolpin · 3 shared papers, 2020–2024 · strength 0.38
  16. Keith D. Lillemoe · 3 shared papers, 2020–2022 · strength 0.36
  17. Anne Pannekoek · 1 shared paper, 2026 · strength 0.33
  18. Catherine S. Valukas · 1 shared paper, 2022 · strength 0.33
  19. Cristina R. Ferrone · 2 shared papers, 2020–2024 · strength 0.32
  20. Ishan Roy · 1 shared paper, 2026 · strength 0.29
  21. Sahil Doshi · 1 shared paper, 2023 · strength 0.26
  22. Marc Altimari · 1 shared paper, 2023 · strength 0.26
  23. Judy Caroline Boughey · 1 shared paper, 2026 · strength 0.25
  24. Dhruv J. Patel · 1 shared paper, 2026 · strength 0.25
  25. Brett Logan Ecker · 1 shared paper, 2026 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.